<DOC>
	<DOCNO>NCT02773355</DOCNO>
	<brief_summary>This trial conduct North America . The aim investigate timely detection pancreatitis case well case suspicion serious non-serious adverse reaction possibly probably related Saxenda® Mexican patient .</brief_summary>
	<brief_title>Timely Detection Treatment Emergent Serious Non-serious Adverse Events Saxenda® Mexican Patients</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Signed consent obtain studyrelated activity ( studyrelated activity procedure relate recording data accord protocol ) The decision initiate treatment commercially available Saxenda® make patient/Legally Acceptable Representative ( LAR ) treat physician independently decision include patient study Obese patient ( BMI equal 30 kg/m^2 ) overweight patient ( BMI Equal 27 kg/m^2 ) least one weight relate comorbidity accord Saxenda® label text Mexico Age equal 18 year time signing informed consent Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Hypersensitivity Saxenda® excipients Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure require local law practice ) Diagnosis type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>